Skip to main content
Erschienen in: Inflammation 6/2014

01.12.2014

STAT1 Regulates MD-2 Expression in Monocytes of Sepsis via miR-30a

verfasst von: Yanhong Wang, Tiehua Li, Benquan Wu, Hui Liu, Jinmei Luo, Dingyun Feng, Yunfeng Shi

Erschienen in: Inflammation | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Sepsis is a major cause of morbidity and mortality in critically ill patients. MD-2 is a 25-kDa lipopolysaccharide (LPS)-binding protein that forms a heterodimer with TLR42, but its regulation in sepsis is not clear. This study aims to investigate the molecular mechanism of regulation of MD-2. Inflammation cytokines in monocytes were analyzed by real-time RT-PCR and ELISA, and it was found that IL-10 was elevated significantly in the monocytes with LPS treatment. And then, when the cells were treated with IL-10, STAT1 was activated in the monocytes using Western blotting. It was also found that STAT1 could enhance MD-2 expression on transcriptional and posttranscriptional levels. Finally, miR-30a was predicted to the molecule that may regulate STAT1 expression. It was verified that STAT1 was a new target gene of miR-30a. miR-30a could inhibit IL-10-induced cytokine release by targeting STAT1–MD-2 in monocytes. In conclusion, this study for the first time demonstrated that miR-30a inhibits MD-2 expression by targeting of STAT1 in human monocytes.
Literatur
1.
Zurück zum Zitat Liesenfeld, O., L. Lehman, K.P. Hunfeld, and G. Kost. 2014. Molecular diagnosis of sepsis: new aspects and recent developments. Eur J Microbiol Immunol (Bp) 4(1): 1–25.CrossRef Liesenfeld, O., L. Lehman, K.P. Hunfeld, and G. Kost. 2014. Molecular diagnosis of sepsis: new aspects and recent developments. Eur J Microbiol Immunol (Bp) 4(1): 1–25.CrossRef
2.
Zurück zum Zitat López-Abarrategui, C., A. Del Monte-Martínez, O. Reyes-Acosta, O.L. Franco, and A.J. Otero-González. 2013. LPS inmobilization on porous and non-porous supports as an approach for the isolation of anti-LPS host-defense peptides. Frontiers in Microbiology 4: 389.PubMedCentralPubMedCrossRef López-Abarrategui, C., A. Del Monte-Martínez, O. Reyes-Acosta, O.L. Franco, and A.J. Otero-González. 2013. LPS inmobilization on porous and non-porous supports as an approach for the isolation of anti-LPS host-defense peptides. Frontiers in Microbiology 4: 389.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Hotchkiss, R.S., G. Monneret, and D. Payen. 2013. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature Reviews. Immunology 13(12): 862–874.PubMedCrossRef Hotchkiss, R.S., G. Monneret, and D. Payen. 2013. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature Reviews. Immunology 13(12): 862–874.PubMedCrossRef
5.
Zurück zum Zitat Boomer, J.S., J.M. Green, and R.S. Hotchkiss. 2014. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 5(1): 45–56.PubMedCentralPubMedCrossRef Boomer, J.S., J.M. Green, and R.S. Hotchkiss. 2014. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence 5(1): 45–56.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Park, B.S., and J.O. Lee. 2013. Recognition of lipopolysaccharide pattern by TLR4 complexes. Experimental & Molecular Medicine 45: e66.CrossRef Park, B.S., and J.O. Lee. 2013. Recognition of lipopolysaccharide pattern by TLR4 complexes. Experimental & Molecular Medicine 45: e66.CrossRef
7.
Zurück zum Zitat Christiansen, D., O.L. Brekke, J. Stenvik, J.D. Lambris, T. Espevik, and T.E. Mollnes. 2012. Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Advances in Experimental Medicine and Biology 946: 237–251.PubMedCrossRef Christiansen, D., O.L. Brekke, J. Stenvik, J.D. Lambris, T. Espevik, and T.E. Mollnes. 2012. Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Advances in Experimental Medicine and Biology 946: 237–251.PubMedCrossRef
8.
Zurück zum Zitat Kimoto, M., K. Nagasawa, and K. Miyake. 2003. Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scandinavian Journal of Infectious Diseases 35(9): 568–572.PubMedCrossRef Kimoto, M., K. Nagasawa, and K. Miyake. 2003. Role of TLR4/MD-2 and RP105/MD-1 in innate recognition of lipopolysaccharide. Scandinavian Journal of Infectious Diseases 35(9): 568–572.PubMedCrossRef
9.
Zurück zum Zitat Miyake, K. 2003. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. International Immunopharmacology 3(1): 119–128.PubMedCrossRef Miyake, K. 2003. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. International Immunopharmacology 3(1): 119–128.PubMedCrossRef
10.
Zurück zum Zitat Vandooren, J., P.E. Van den Steen, and G. Opdenakker. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Critical Reviews in Biochemistry and Molecular Biology 48(3): 222–272.PubMedCrossRef Vandooren, J., P.E. Van den Steen, and G. Opdenakker. 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Critical Reviews in Biochemistry and Molecular Biology 48(3): 222–272.PubMedCrossRef
11.
Zurück zum Zitat Sinkovics, J.G. 2012. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). International Journal of Oncology 40(2): 305–349.PubMed Sinkovics, J.G. 2012. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review). International Journal of Oncology 40(2): 305–349.PubMed
12.
Zurück zum Zitat Ivády, B., B.J. Béres, and D. Szabó. 2011. Recent advances in sepsis research: novel biomarkers and therapeutic targets. Current Medicinal Chemistry 18(21): 3211–3225.PubMedCrossRef Ivády, B., B.J. Béres, and D. Szabó. 2011. Recent advances in sepsis research: novel biomarkers and therapeutic targets. Current Medicinal Chemistry 18(21): 3211–3225.PubMedCrossRef
13.
Zurück zum Zitat Reid, G., M.B. Kirschner, and N. van Zandwijk. 2011. Circulating microRNAs: association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology 80(2): 193–208.PubMedCrossRef Reid, G., M.B. Kirschner, and N. van Zandwijk. 2011. Circulating microRNAs: association with disease and potential use as biomarkers. Critical Reviews in Oncology/Hematology 80(2): 193–208.PubMedCrossRef
14.
Zurück zum Zitat Hennessy, E.J., A.E. Parker, and L.A. O’Neill. 2010. Targeting Toll-like receptors: emerging therapeutics? Nature Reviews. Drug Discovery 9(4): 293–307.PubMedCrossRef Hennessy, E.J., A.E. Parker, and L.A. O’Neill. 2010. Targeting Toll-like receptors: emerging therapeutics? Nature Reviews. Drug Discovery 9(4): 293–307.PubMedCrossRef
15.
Zurück zum Zitat Biswas, S.K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends in Immunology 30(10): 475–487.PubMedCrossRef Biswas, S.K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends in Immunology 30(10): 475–487.PubMedCrossRef
16.
Zurück zum Zitat Wang, H.J., J. Deng, J.Y. Wang, P.J. Zhang, Z. Xin, K. Xiao, D. Feng, Y.H. Jia, Y.N. Liu, and L.X. Xie. 2014. Serum miR-122 levels are related to coagulation disorders in sepsis patients. Clinical Chemistry and Laboratory Medicine 14: 1–7. Wang, H.J., J. Deng, J.Y. Wang, P.J. Zhang, Z. Xin, K. Xiao, D. Feng, Y.H. Jia, Y.N. Liu, and L.X. Xie. 2014. Serum miR-122 levels are related to coagulation disorders in sepsis patients. Clinical Chemistry and Laboratory Medicine 14: 1–7.
17.
Zurück zum Zitat Wang, Z.H., Y.B. Liang, H. Tang, Z.B. Chen, Z.Y. Li, X.C. Hu, and Z.F. Ma. 2013. Dexamethasone down-regulates the expression of microRNA-155 in the livers of septic mice. PloS One 8(11): e80547.PubMedCentralPubMedCrossRef Wang, Z.H., Y.B. Liang, H. Tang, Z.B. Chen, Z.Y. Li, X.C. Hu, and Z.F. Ma. 2013. Dexamethasone down-regulates the expression of microRNA-155 in the livers of septic mice. PloS One 8(11): e80547.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Ma, Y., D. Vilanova, K. Atalar, O. Delfour, J. Edgeworth, M. Ostermann, M. Hernandez-Fuentes, S. Razafimahatratra, B. Michot, D.H. Persing, I. Ziegler, B. Törös, P. Mölling, P. Olcén, R. Beale, and G.M. Lord. 2013. Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PloS One 8(10): e75918.PubMedCentralPubMedCrossRef Ma, Y., D. Vilanova, K. Atalar, O. Delfour, J. Edgeworth, M. Ostermann, M. Hernandez-Fuentes, S. Razafimahatratra, B. Michot, D.H. Persing, I. Ziegler, B. Törös, P. Mölling, P. Olcén, R. Beale, and G.M. Lord. 2013. Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis. PloS One 8(10): e75918.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Wu Y, Yang L, Mei X, Yu Y. Selective inhibition of STAT1 reduces spinal cord injury in mice. Neurosci Lett. 2013. Wu Y, Yang L, Mei X, Yu Y. Selective inhibition of STAT1 reduces spinal cord injury in mice. Neurosci Lett. 2013.
20.
Zurück zum Zitat Trilling, M., V.T. Le, J. Rashidi-Alavijeh, B. Katschinski, J. Scheller, S. Rose-John, G.E. Androsiac, S. Jonjic, V. Poli, K. Pfeffer, and H. Hengel. 2014. “Activated” STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. Journal of Immunology 192(1): 447–458.CrossRef Trilling, M., V.T. Le, J. Rashidi-Alavijeh, B. Katschinski, J. Scheller, S. Rose-John, G.E. Androsiac, S. Jonjic, V. Poli, K. Pfeffer, and H. Hengel. 2014. “Activated” STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. Journal of Immunology 192(1): 447–458.CrossRef
21.
Zurück zum Zitat Lin, L., J. Hou, F. Ma, P. Wang, X. Liu, N. Li, J. Wang, Q. Wang, and X. Cao. 2013. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. Journal of Immunology 191(7): 3896–3904.CrossRef Lin, L., J. Hou, F. Ma, P. Wang, X. Liu, N. Li, J. Wang, Q. Wang, and X. Cao. 2013. Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. Journal of Immunology 191(7): 3896–3904.CrossRef
22.
Zurück zum Zitat Nieminen, J.K., M. Niemi, T. Sipponen, H.M. Salo, P. Klemetti, M. Färkkilä, J. Vakkila, and O. Vaarala. 2013. Dendritic cells from Crohn’s disease patients show aberrant STAT1 and STAT3 signaling. PloS One 8(8): e70738.PubMedCentralPubMedCrossRef Nieminen, J.K., M. Niemi, T. Sipponen, H.M. Salo, P. Klemetti, M. Färkkilä, J. Vakkila, and O. Vaarala. 2013. Dendritic cells from Crohn’s disease patients show aberrant STAT1 and STAT3 signaling. PloS One 8(8): e70738.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Meisch, J.P., R.M. Vogel, D.M. Schlatzer, X. Li, M.R. Chance, and A.D. Levine. 2013. Human β-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokine synthesis in T cells. Journal of Leukocyte Biology 94(3): 459–471.PubMedCentralPubMedCrossRef Meisch, J.P., R.M. Vogel, D.M. Schlatzer, X. Li, M.R. Chance, and A.D. Levine. 2013. Human β-defensin 3 induces STAT1 phosphorylation, tyrosine phosphatase activity, and cytokine synthesis in T cells. Journal of Leukocyte Biology 94(3): 459–471.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Singh, U.P., N.P. Singh, H. Guan, B. Busbee, R.L. Price, D.D. Taub, M.K. Mishra, R. Fayad, M. Nagarkatti, and P.S. Nagarkatti. 2013. Leptin antagonist ameliorates chronic colitis in IL-10−/− mice. Immunobiology 218(12): 1439–1451.PubMedCrossRef Singh, U.P., N.P. Singh, H. Guan, B. Busbee, R.L. Price, D.D. Taub, M.K. Mishra, R. Fayad, M. Nagarkatti, and P.S. Nagarkatti. 2013. Leptin antagonist ameliorates chronic colitis in IL-10/ mice. Immunobiology 218(12): 1439–1451.PubMedCrossRef
25.
Zurück zum Zitat Fontan, L., and A. Melnick. 2013. Discovering what makes STAT signaling TYK in T-ALL. Cancer Discov 3(5): 494–496.PubMedCrossRef Fontan, L., and A. Melnick. 2013. Discovering what makes STAT signaling TYK in T-ALL. Cancer Discov 3(5): 494–496.PubMedCrossRef
26.
Zurück zum Zitat Haque, A., N. Koide, E. Odkhuu, B. Tsolmongyn, Y. Naiki, T. Komatsu, T. Yoshida, and T. Yokochi. 2014. Mouse pyrin and HIN domain family member 1 (pyhin1) protein positively regulates LPS-induced IFN-β and NO production in macrophages. Innate Immunity 20(1): 40–48.PubMedCrossRef Haque, A., N. Koide, E. Odkhuu, B. Tsolmongyn, Y. Naiki, T. Komatsu, T. Yoshida, and T. Yokochi. 2014. Mouse pyrin and HIN domain family member 1 (pyhin1) protein positively regulates LPS-induced IFN-β and NO production in macrophages. Innate Immunity 20(1): 40–48.PubMedCrossRef
27.
Zurück zum Zitat Pattison, M.J., K.F. MacKenzie, S.E. Elcombe, and J.S. Arthur. 2013. IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages. FEBS Letters 587(10): 1496–1503.PubMedCentralPubMedCrossRef Pattison, M.J., K.F. MacKenzie, S.E. Elcombe, and J.S. Arthur. 2013. IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages. FEBS Letters 587(10): 1496–1503.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Matsukawa, A. 2007. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Medica Okayama 61(5): 239–245.PubMed Matsukawa, A. 2007. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Medica Okayama 61(5): 239–245.PubMed
29.
Zurück zum Zitat Klinman, D.M., D. Tross, S. Klaschik, H. Shirota, and T. Sato. 2009. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals of the New York Academy of Sciences 1175: 80–88.PubMedCrossRef Klinman, D.M., D. Tross, S. Klaschik, H. Shirota, and T. Sato. 2009. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Annals of the New York Academy of Sciences 1175: 80–88.PubMedCrossRef
Metadaten
Titel
STAT1 Regulates MD-2 Expression in Monocytes of Sepsis via miR-30a
verfasst von
Yanhong Wang
Tiehua Li
Benquan Wu
Hui Liu
Jinmei Luo
Dingyun Feng
Yunfeng Shi
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9922-1

Weitere Artikel der Ausgabe 6/2014

Inflammation 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.